Buy & Sell Expedia Group Inc (EXPE) – Expedia Group Inc Price Today
Aura AI Summary
Key Stats
- $27.11BMarket Cap
- Consumer CyclicalSector
- -21.6%3M Drawdown
- $26.02BEnterprise Value
- 0.78%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 47 daysTypical Hold Time
Expedia Group Inc (EXPE) is currently valued at a market capitalization of $27.11B, with an enterprise value of $26.02B. Over the past 52 weeks, Expedia Group Inc has traded between a low of $161.99 and a high of $301.31, highlighting its annual price range. Over the past three months, Expedia Group Inc has recorded a drawdown of -21.6%, reflecting recent price volatility. Expedia Group Inc offers a dividend yield of 0.78%, with the most recent dividend of $0.48 paid on 28 May 26. On average, investors hold Expedia Group Inc for approximately 47 days, indicating typical investor behavior on the platform.
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Most Recent News
Investigation into Wealthfront's securities fraud continues amid sharp stock drops and deposit declines.
Glancy Prongay & Murray LLP is investigating Wealthfront Corporation for potential securities law violations after the company reported significant financial setbacks. Wealthfront's stock fell sharply following disclosures of large net deposit outflo...

ControlUp named Leader for third year in Gartner's 2026 Digital Employee Experience Magic Quadrant.
ControlUp has been recognized as a Leader for the third consecutive year in Gartner's 2026 Magic Quadrant for Digital Employee Experience (DEX) Management Tools. This highlights ControlUp's innovation in Autonomous Endpoint Management using agentic A...

Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...
